Poging GOUD - Vrij

Where AR & VR Are Headed In Life Sciences Industry?

BioSpectrum Asia

|

March 2020

The rise of MedTech is transforming the healthcare industry, as augmented reality (AR) and virtual reality (VR) have pushed the right buttons with players by offering high-tech solutions to fix prevailing challenges in medical training, diagnostics, and treatments. The development of state-of-the-art technologies such as digital reality has disrupted the industrial scenario, and tools such as AR and VR have gained immense popularity in one stroke. Yet, the industrial adoption of digital reality remained significantly low since its inception, and the application range was fairly narrow due to low penetration and high cost of AR and VR tools.

Where AR & VR Are Headed In Life Sciences Industry?

The unprecedented growth of the electronics and telecommunications industry marks this decade as the golden period for advancements in technology. Next-generation technologies have given modern electronic appliances advanced processing controls, which enable end-users to experience the new aspects of the real world.

Hearteningly, though, the technology has witnessed widespread implementation in the recent years. In 2017, the global market for virtual reality accounted for nearly $ 3 billion, and the valuation is set to grow at least twice as large by 2022. Now, augmented reality (AR) and virtual reality (VR) tools are taking over efficiency- and testing-related tasks in a widening range of industrial applications.

Seeing is believing’

Despite the advent of many groundbreaking inventions and medical discoveries, the healthcare industry is still grappling to find a cure for many deadly diseases. As there is no loss costlier than the loss of a human life, healthcare industry has begun to invest in AR and VR driven simulation tools to discover new and efficient ways to save more lives.

Healthcare industry is one of the very first and very few industries to embrace digital reality on a significantly large scale. In 2018, the adoption of medical devices integrated with AR and VR technologies in the healthcare industry generated a revenue of $ 600 million. Taking into consideration the rate at which the penetration of digital reality is increasing in this landscape, the global market for AR and VR in healthcare is expected to reach a valuation of more than $ 15 billion by 2026. The healthcare AR and VR market is set to witness unprecedented growth at an astonishing CAGR (compound annual growth rate) of nearly 49 per cent between 2018 and 2026.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

India's Final Mile to TB Elimination

As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Korea builds AI-engineered nasal spray antiviral platform

A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action

Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.

time to read

4 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector

Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.

time to read

1 min

BioSpectrum Asia Jan 2026

Translate

Share

-
+

Change font size